|
|
|
|
LEADER |
01836nam a2200253 u 4500 |
001 |
EB002000901 |
003 |
EBX01000000000000001163802 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
210907 r ||| eng |
100 |
1 |
|
|a Jahagirdar, Deepa
|
245 |
0 |
0 |
|a Naltrexone for opioid use disorders
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Deepa Jahagirdar, Mary-Doug Wright
|
250 |
|
|
|a Version 1.0
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c July 4, 2017, 2017
|
300 |
|
|
|a 1 PDF file (38 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
700 |
1 |
|
|a Wright, Mary-Doug
|e [author]
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK525041
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a The Food and Drug Administration in the U.S. approved naltrexone (XR-NTX) in 2010, however, in Canada extended-release naltrexone is only available through the Health Canada's Special Access Programme or for research. Given the relative novelty of XR-NTX, its effectiveness compared with oral naltrexone remains unclear, despite the potential for higher adherence. In addition, the clinical and cost effectiveness of both these options is relevant because having multiple treatment options can support stakeholders to treat opioid dependence. This review assesses the clinical effectiveness, cost-effectiveness and guidelines for oral and injectable naltrexone to treat opioid dependence to inform policy-making in Canada to address the increasing burden of opioid use disorders
|